Ozlen Saglam, M.D.

  • Associate Professor of Pathology & Laboratory Medicine, School of Medicine

Education and training

  • Degrees

    • M.D., 1992, Marmara University Medical School

  • Residency

    • Anatomic and Clinical Pathology Residency, Henry Ford Hospital, Detroit, Michigan, 2002-2006

  • Fellowship

    • Cytopathology Fellowship, Henry Ford Hospital, Detroit, Michigan, 2007-2008
    • Oncologic Surgical Pathology Fellowship, Moffitt Cancer Center, Tampa, Florida, 2006-2007
    • Head and Neck Oncology Fellowship, Sisters’ Hospital, Buffalo, New York, 1999-2000
    • Research Fellowship University of Louisville, Louisville, Kentucky, 1998-1999

  • Certifications

    • Anatomic and Clinical Pathology (American Board of Pathology), 2007

Publications

Selected publications

  • Reid BM, Vyas S, Chen Z, Chen A, Kanetsky PA, Permuth JB, Sellers TA, Saglam O. Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma. BMC Cancer. In press.
  • Saglam O, Tang Z, Tang G, Medeiros LJ, Toruner GA. KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma. PLoS One. 2020 Sep 2;15(9):e0238477.
  • Saglam O, Lin DI, Steele C, Killian J, Wenham RM. A sporadic Gastric-type Endocervical Adenocarcinoma with Endometrial Involvement and Bilateral Ovarian metastasis, A Case Report. Gynecol Oncol Rep. 2020 Apr 18;32:100572.
  • Saglam O, Zhou J, Wang X, Conejo-Garcia JR. PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma. Int J Gynecol Pathol. 2020 Sep;39(5):428-435.
  • Saglam O, Naqvi SMH, Zhang Y, Mesa T, Teer JK, Yoder S, Lee J, Messina J. Female Genitourinary Tract Melanoma: Mutation Analysis with Clinicopathologic Correlation, a single-institution experience. Melanoma Res. 2018 Dec; 28(6):586-591.
  • Saglam O, Conejo-Garcia J. PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer. Integr Cancer Sci Ther. 2018;5(2). 10.15761/ICST.1000272.
  • Saglam O, Xiong Y, Marchion DC, Strosberg C, Wenham RM, Johnson JJ, Daryoush S, Cubitt C, Magliocco AM. ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy. Cancer Control. 2017 Jan;24(1):89-95.
  • Pribish A, Saglam O, Weinfurtner RJ. Estrogen Receptor-Positive Primary Squamous Cell Carcinoma of the Breast. Radiology Case Reports. Radiol Case Rep. 2017 Feb 4;12(2):211-214.
  • Von Wahlde MK, Timms KM, Chagpar AB, Wali VB, Jiang T, Bossuyt V, Saglam O, Reid JE, Gutin A, Neff C, Lanchbury JS, Hatzis C, Hofstatter E, Pustzai L. Intratumor heterogeneity of homologous recombination deficiency in primary breast cancer. Clin Cancer Res. 2017 Mar 1;23(5):1193-1199.

Publications